{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:07:22Z","timestamp":1792181242953,"version":"4.4.0"},"reference-count":8,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:p>This Viewpoint describes what dermatologists should know about doxycycline postexposure prophylaxis (doxyPEP) for bacterial sexually transmitted infection (STI) prevention, specifically syphilis, chlamydia, and gonorrhea.<\/jats:p>","DOI":"10.1001\/jamadermatol.2024.4567","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T16:32:20Z","timestamp":1731515540000},"page":"7","source":"Crossref","is-referenced-by-count":4,"title":["Doxycycline Postexposure Prophylaxis (DoxyPEP) for Bacterial STI Prevention"],"prefix":"10.1001","volume":"161","author":[{"given":"Muhammad H.","family":"Junejo","sequence":"first","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia L.","family":"Marcus","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Harvard Pilgrim Health Care Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth A.","family":"Katz","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Kaiser Permanente San Francisco Medical Center, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"dvp240007r1","first-page":"566","article-title":"Doxycycline postexposure prophylaxis for prevention of sexually transmitted infections.","volume":"31","author":"Cannon","year":"2023","journal-title":"Top Antivir Med"},{"issue":"2","key":"dvp240007r2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7302a1","article-title":"CDC clinical guidelines on the use of doxycycline postexposure prophylaxis for bacterial sexually transmitted infection prevention, United States.","volume":"73","author":"Bachmann","year":"2024","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"dvp240007r4","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S1473-3099(17)30725-9","article-title":"Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.","volume":"18","author":"Molina","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"14","key":"dvp240007r5","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa2211934","article-title":"Postexposure doxycycline to prevent bacterial sexually transmitted infections.","volume":"388","author":"Luetkemeyer","year":"2023","journal-title":"N Engl J Med"},{"key":"dvp240007r6","doi-asserted-by":"publisher","first-page":"S1473","DOI":"10.1016\/S1473-3099(24)00236-6","article-title":"Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2?\u00d7?2 factorial design.","author":"Molina","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"25","key":"dvp240007r7","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1056\/NEJMoa2304007","article-title":"Doxycycline prophylaxis to prevent sexually transmitted infections in women.","volume":"389","author":"Stewart","year":"2023","journal-title":"N Engl J Med"},{"key":"dvp240007r3","unstructured":"Centers for Disease Control and Prevention. National overview of STIs, 2022. Accessed August 16, 2024. https:\/\/www.cdc.gov\/std\/statistics\/2022\/overview.htm."},{"key":"dvp240007r8","unstructured":"Scott? H, Roman? J, Spinelli? MA, . Doxycycline PEP: high uptake and significant decline in STIs after clinical implementation. 2024. Accessed June 13, 2024. https:\/\/www.croiconference.org\/abstract\/doxycycline-pep-high-uptake-and-significant-decline-in-stis-after-clinical-implementation\/"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2826309\/jamadermatology_junejo_2024_vp_240007_1736781505.43474.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T16:01:17Z","timestamp":1736956877000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2826309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.4567","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}